Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors

Introduction: Chronic obstructive pulmonary disease (COPD) and emphysema are independent risk factors for lung cancer development and have been independently associated with longer overall survival (OS) in patients with NSCLC treated with immune checkpoint inhibitors (ICIs). However, their combined...

Descripción completa

Detalles Bibliográficos
Autores: Di Frisco M, Sanmamed MF, Ferrandez JM, Vilalta A, Sogbe M, García-Goñi M, Martin-Palmero Á, Aso-Gonzalez S, Nadal E, Signes-Costa J, Gambardella V, Manzaneque VS, Martin P, Insa A, Franco J, Lores C, de-Torres JP
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p20468
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/20468
Access Level:acceso abierto
Palabra clave:COPD
Emphysema
Non-small cell lung cancer
Immune checkpoint inhibitors
id ES_a7478ebce89d5f754f112e1b0c5746fc
oai_identifier_str oai:incliva.fundanetsuite.com:p20468
network_acronym_str ES
network_name_str España
repository_id_str
spelling Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint InhibitorsDi Frisco MSanmamed MFFerrandez JMVilalta ASogbe MGarcía-Goñi MMartin-Palmero ÁAso-Gonzalez SNadal ESignes-Costa JGambardella VManzaneque VSMartin PInsa AFranco JLores Cde-Torres JPCOPDEmphysemaNon-small cell lung cancerImmune checkpoint inhibitorsIntroduction: Chronic obstructive pulmonary disease (COPD) and emphysema are independent risk factors for lung cancer development and have been independently associated with longer overall survival (OS) in patients with NSCLC treated with immune checkpoint inhibitors (ICIs). However, their combined impact on prognosis remains unclear. This study evaluates emphysema as a prognostic factor in patients with COPD with advanced NSCLC (aNSCLC) undergoing immunotherapy. Methods: This study included patients with aNSCLC with COPD (defined by spirometry) treated with single-agent ICI as first-or second-line treatment, from 2013 to 2024. Patients were classified based on visually detected emphysema on chest computed tomography. Results: The study included 111 patients with COPD, of whom 77 had coexisting emphysema. Patients with COPD and emphysema had significantly longer OS compared with those without emphysema (17.3 versus 8.5 mo, p = 0.008), with a nonsignificant trend toward improved progression-free survival (3.3 versus 2.4 mo, p = 0.641). Emphysema remained an independent factor of better OS in multivariate analysis (hazard ratio: 0.49; 95% confidence interval: 0.30-0.81). Adverse event rates were similar regardless of emphysema status (p = 0.455). Conclusions: This study suggests that visually detected emphysema on chest computed tomography could be a potential prognostic marker in patients with aNSCLC with COPD receiving ICIs. Further studies are guaranteed to confirm these findings. (c) 2025 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ELSEVIER SCIENCE INC2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/20468Journal of Thoracic OncologyISSN: 15560864ISSNe: 15561380reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p204682026-06-07T16:35:31Z
dc.title.none.fl_str_mv Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
title Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
spellingShingle Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
Di Frisco M
COPD
Emphysema
Non-small cell lung cancer
Immune checkpoint inhibitors
title_short Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
title_full Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
title_fullStr Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
title_full_unstemmed Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
title_sort Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
dc.creator.none.fl_str_mv Di Frisco M
Sanmamed MF
Ferrandez JM
Vilalta A
Sogbe M
García-Goñi M
Martin-Palmero Á
Aso-Gonzalez S
Nadal E
Signes-Costa J
Gambardella V
Manzaneque VS
Martin P
Insa A
Franco J
Lores C
de-Torres JP
author Di Frisco M
author_facet Di Frisco M
Sanmamed MF
Ferrandez JM
Vilalta A
Sogbe M
García-Goñi M
Martin-Palmero Á
Aso-Gonzalez S
Nadal E
Signes-Costa J
Gambardella V
Manzaneque VS
Martin P
Insa A
Franco J
Lores C
de-Torres JP
author_role author
author2 Sanmamed MF
Ferrandez JM
Vilalta A
Sogbe M
García-Goñi M
Martin-Palmero Á
Aso-Gonzalez S
Nadal E
Signes-Costa J
Gambardella V
Manzaneque VS
Martin P
Insa A
Franco J
Lores C
de-Torres JP
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COPD
Emphysema
Non-small cell lung cancer
Immune checkpoint inhibitors
topic COPD
Emphysema
Non-small cell lung cancer
Immune checkpoint inhibitors
description Introduction: Chronic obstructive pulmonary disease (COPD) and emphysema are independent risk factors for lung cancer development and have been independently associated with longer overall survival (OS) in patients with NSCLC treated with immune checkpoint inhibitors (ICIs). However, their combined impact on prognosis remains unclear. This study evaluates emphysema as a prognostic factor in patients with COPD with advanced NSCLC (aNSCLC) undergoing immunotherapy. Methods: This study included patients with aNSCLC with COPD (defined by spirometry) treated with single-agent ICI as first-or second-line treatment, from 2013 to 2024. Patients were classified based on visually detected emphysema on chest computed tomography. Results: The study included 111 patients with COPD, of whom 77 had coexisting emphysema. Patients with COPD and emphysema had significantly longer OS compared with those without emphysema (17.3 versus 8.5 mo, p = 0.008), with a nonsignificant trend toward improved progression-free survival (3.3 versus 2.4 mo, p = 0.641). Emphysema remained an independent factor of better OS in multivariate analysis (hazard ratio: 0.49; 95% confidence interval: 0.30-0.81). Adverse event rates were similar regardless of emphysema status (p = 0.455). Conclusions: This study suggests that visually detected emphysema on chest computed tomography could be a potential prognostic marker in patients with aNSCLC with COPD receiving ICIs. Further studies are guaranteed to confirm these findings. (c) 2025 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
publishDate 2026
dc.date.none.fl_str_mv 2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/20468
url https://incliva.portalinvestigacion.com/publicaciones/20468
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER SCIENCE INC
publisher.none.fl_str_mv ELSEVIER SCIENCE INC
dc.source.none.fl_str_mv Journal of Thoracic Oncology
ISSN: 15560864
ISSNe: 15561380
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415765260632064
score 15,81155

Similares en LA Referencia